公开(公告)号：CA2781433A1

公开(公告)日：2011-05-26

申请号：CA2781433

申请日：2010-11-19

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K38/38 ,  A61K35/76 ,  A61K38/16 ,  A61P35/04 ,  C07K14/76

Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.

公开(公告)号：CA2781433C

公开(公告)日：2019-04-09

申请号：CA2781433

申请日：2010-11-19

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K38/38 ,  A61K38/16 ,  A61P35/04 ,  C07K14/09 ,  C07K14/76

Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.

公开(公告)号：AU2010321830B2

公开(公告)日：2015-06-11

申请号：AU2010321830

申请日：2010-11-19

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K38/38 ,  A61K38/16 ,  A61K47/48 ,  C07K14/76

Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment

公开(公告)号：AU2010321830A1

公开(公告)日：2012-07-05

申请号：AU2010321830

申请日：2010-11-19

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: C07K14/76 ,  A61K38/16 ,  A61K38/38 ,  A61K47/48

Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment . In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.

公开(公告)号：WO2005121169A3

公开(公告)日：2006-03-30

申请号：PCT/US2005020355

申请日：2005-06-08

Applicant: ACADEMIA SINICA ,  LIANG SHU-MEI ,  PENG JEI-MING ,  LIANG CHI-MING

Inventor： LIANG SHU-MEI ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K39/12 ,  A61K38/00 ,  A61K38/06 ,  A61K38/16 ,  A61K39/00 ,  A61K39/125 ,  A61K39/135 ,  C07K1/113 ,  C07K14/005 ,  C07K14/09 ,  C12N7/00 ,  C12N7/01

CPC classification number: C07K14/005 ,  A61K31/7088 ,  A61K38/162 ,  A61K39/00 ,  A61K39/12 ,  A61K39/135 ,  A61K2039/523 ,  C07K1/1136 ,  C12N2770/32122 ,  C12N2770/32133

Abstract: An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.

Abstract translation: 口蹄疫病毒的分离的水溶性VP1多肽和编码该多肽的核酸。 还公开了含有多肽或核酸的药物组合物和诱导凋亡和治疗凋亡相关病症的相关方法。

公开(公告)号：EP1765392A4

公开(公告)日：2007-10-17

申请号：EP05757499

申请日：2005-06-08

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K39/12 ,  A61K38/00 ,  A61K38/06 ,  A61K38/16 ,  A61K39/00 ,  A61K39/125 ,  A61K39/135 ,  C07K1/113 ,  C07K14/005 ,  C07K14/09 ,  C12N7/00 ,  C12N7/01

CPC classification number: C07K14/005 ,  A61K31/7088 ,  A61K38/162 ,  A61K39/00 ,  A61K39/12 ,  A61K39/135 ,  A61K2039/523 ,  C07K1/1136 ,  C12N2770/32122 ,  C12N2770/32133

公开(公告)号：EP2501402A4

公开(公告)日：2013-05-01

申请号：EP10832290

申请日：2010-11-19

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K38/38 ,  A61K47/48 ,  C07K14/76

CPC classification number: A61K38/385 ,  A61K38/162 ,  A61K38/38 ,  A61K45/06 ,  A61K47/643 ,  A61N5/10 ,  C07K14/765 ,  C12N7/00 ,  C12N2770/32133

Abstract: Fibrillar human serum albumin was shown to be effective in the treatment of various types of cancers. Methods and compositions are disclosed for using fibrillar human serum albumin as a medicament to treat subjects having cancer.